Abastatins A-C, novel depsipeptides, potently inhibit cathepsin D in picomolar range
Background
Cathepsin D is an aspartic protease implicated in the progression of various diseases, including cancer and neurodegenerative disorders. Current therapeutic strategies often lack specificity or encounter off-target effects. Statine (Sta)-containing natural products are recognized for their ability to inhibit cathepsin D, offering a promising avenue for drug discovery. This study explores novel Sta-containing depsipeptides from marine cyanobacteria, aiming to identify highly potent and selective inhibitors to address the unmet need for effective cathepsin D modulation.
Study Design
Researchers isolated three novel Sta-containing depsipeptides, abastatins A-C, from a marine Okeania sp. cyanobacterium collected in Japan. Their chemical structures were determined through comprehensive spectroscopic analyses, including NMR and mass spectrometry, combined with derivatization and degradation reactions. The study also involved molecular docking simulations to propose plausible binding poses of abastatins A-C with cathepsin D, and to elucidate a new structure-activity relationship (SAR) that enhances inhibitory potency against the enzyme.
Results
Abastatins A-C were identified as novel Sta-containing natural products. These depsipeptides exhibited exceptionally potent inhibitory activity against cathepsin D. Specifically, abastatins A-C demonstrated IC50 values in the picomolar range, making them the most potent cathepsin D inhibitors reported from Sta-containing natural products to date. Spectroscopic analyses confirmed their unique structures. Furthermore, the study proposed specific docking poses for abastatins A-C within the cathepsin D active site, revealing key structural features responsible for their high affinity. This led to the description of a novel structure-activity relationship. The findings highlight the potential of marine cyanobacteria as a source for highly effective enzyme inhibitors.
Abastatins A-C exhibit the most potent cathepsin D inhibitory activities reported thus far with IC50 values in the picomolar range.
Key Findings
- Three new Sta-containing depsipeptides, abastatins A-C, were isolated from a marine Okeania sp. cyanobacterium.
- Abastatins A-C are the most potent cathepsin D inhibitors reported from Sta-containing natural products.
- Abastatins A-C exhibit cathepsin D inhibitory activities with IC50 values in the picomolar range.
- Plausible docking poses for abastatins A-C bound to cathepsin D were proposed.
- A new structure-activity relationship for enhancing cathepsin D inhibitory potency was described.
Why It Matters
This discovery of Abastatins A-C with picomolar potency against cathepsin D represents a significant advancement in the search for highly effective enzyme inhibitors. For researchers and drug developers, these compounds provide novel scaffolds for designing more potent and selective therapeutics targeting cathepsin D, which is crucial in cancer and neurodegenerative diseases. While currently an in-vitro finding, the unprecedented potency suggests a strong foundation for preclinical development. Understanding the new structure-activity relationship could guide the synthesis of optimized analogs, potentially leading to future clinical candidates. This work underscores the vast untapped potential of marine natural products for pharmaceutical innovation.
abastatins-a-c
cathepsin-d
enzyme-inhibitor
depsipeptide
natural-product
marine-cyanobacteria